Di Perri Giovanni, Aguilar Marucco Diego, Mondo Alessandra, Gonzalez de Requena Daniel, Audagnotto Sabrina, Gobbi Federico, Bonora Stefano
Department of Infectious Diseases, University of Torino, Turin, Italy.
Expert Opin Drug Saf. 2005 Sep;4(5):821-36. doi: 10.1517/14740338.4.5.821.
Worldwide, tuberculosis (TB) is one of the most important infectious diseases in subjects with HIV infection. Although effective therapy is available for both conditions, there are major problems in the concurrent treatment of HIV and TB co-infection. In this article the knowledge available on drug-drug interactions between anti-HIV and anti-TB compounds is analysed, particularly with regard to pharmacological interactions secondary to interference with cytochrome P450 enzymes. Within the same setting, facts and possible interpretations of the problems encountered in terms of tolerance and safety of the concurrent treatment of TB and HIV are also reviewed. Current guidelines, as well as additional possible strategies to be adopted in this particular co-morbidity setting are discussed.
在全球范围内,结核病是HIV感染者最重要的传染病之一。尽管针对这两种病症都有有效的治疗方法,但HIV与结核病合并感染的联合治疗存在重大问题。本文分析了抗HIV和抗结核化合物之间药物相互作用的现有知识,特别是关于干扰细胞色素P450酶继发的药理相互作用。在同一背景下,还回顾了结核病和HIV联合治疗在耐受性和安全性方面遇到的问题的事实及可能的解释。讨论了当前的指南以及在这种特殊合并症情况下可采用的其他可能策略。